Tirzep Injection

Drug Name: Tirzepatide

English Name: Tirzepatide

Brand Name: Tirzep/Mounjaro

Dosage Form: Injection

Specifications: 2.5 mg, 5 mg

Manufacturer: ACI Pharmaceuticals

【Indications】

Type 2 Diabetes: For adult patients with type 2 diabetes whose blood glucose remains inadequately controlled despite treatment with metformin and/or sulfonylureas, used as an adjunct to diet and exercise.

Chronic Weight Management**: Indicated for adult patients with obesity (initial Body Mass Index [BMI] ≥30 kg/m²) or overweight (initial BMI ≥27 kg/m²) who have at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, type 2 diabetes), as an adjunct to a reduced-calorie diet and increased physical activity.

【Mechanism of Action】

Tirzepatide is a once-weekly dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It mimics the effects of the body's natural incretin hormones, GIP and GLP-1. By activating GIP and GLP-1 receptors, it increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and reduces food intake, thereby lowering blood glucose levels and promoting weight loss.

【Dosage and Administration】

Route of Administration: Subcutaneous injection; sites include the abdomen, thigh, or upper arm.

Recommended Starting Dose: 2.5 mg once weekly.

Dose Adjustment: The dose may be increased to 5 mg once weekly after at least 4 weeks. Depending on glycemic control, the dose may be further increased; the maximum recommended dose is 15 mg once weekly.

Precautions: Administer on the same day each week, regardless of meal times. If a dose is missed and there are more than 3 days (72 hours) remaining until the next scheduled dose, administer the missed dose as soon as possible and then resume the regular weekly schedule. If there are fewer than 3 days (72 hours) remaining until the next scheduled dose, skip the missed dose and administer the next dose on the scheduled day. [Adverse Reactions]

Common adverse reactions: Gastrointestinal reactions such as nausea, vomiting, diarrhea, decreased appetite, constipation, indigestion, and abdominal pain are relatively common. These usually appear early in treatment and may gradually subside as treatment continues.

Serious adverse reactions: May increase the risk of thyroid C-cell tumors; may also cause acute pancreatitis, characterized by persistent, severe abdominal pain that sometimes radiates to the back; cases of severe hypoglycemia (when used concomitantly with sulfonylureas), acute kidney injury, and retinopathy have also been reported.

[Contraindications]

Contraindicated in patients with a known hypersensitivity to tirzepatide or any of its excipients.

Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC).

Contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

[Precautions]

Risk of hypoglycemia: The risk of hypoglycemia increases when used concomitantly with sulfonylureas; a reduction in the sulfonylurea dosage may be required.

Gastrointestinal reactions: Severe gastrointestinal reactions may lead to complications such as dehydration and acute kidney injury; close monitoring is required.

Thyroid tumor monitoring: Thyroid function should be monitored regularly during treatment; further evaluation is required if abnormalities such as thyroid nodules are detected.

Pregnant and lactating women: There is currently insufficient data regarding the safety of tirzepatide in pregnant and lactating women; use is not recommended.

Pediatric use: The safety and efficacy of tirzepatide in pediatric patients under 18 years of age have not been established.

Anti-counterfeiting verification methods

In-depth analysis: Dosage differences and impact on efficacy between the Chinese and Bangladeshi versions

As a dual receptor agonist (GLP-1/GIP) currently used for weight loss and blood glucose control, the clinical efficacy of tirzepatide is closely linked to the precision of the administered dosage. Recently, many users have encountered issues such as "insufficient dosage" or the "inability to extract the full contents" when injecting different versions of tirzepatide.

This article uses the common Chinese version (10mg/2.4ml) and the Bangladeshi version (2.5mg/0.5ml) as examples to provide an in-depth analysis of the potential dosage pitfalls associated with them. I. The Core Math Problem: Are You Getting the Right Dosage?

The standard initial dose for tirzepatide is typically 2.5 mg per week. Let’s compare the actual drug content of the two versions based on their concentrations:

1. Chinese Version (Example: Multi-dose pen/vial)

Specification: 10 mg / 2.4 ml

Concentration: 4.17 mg/ml

If 0.5 ml is injected: Actual dosage received is 4.17 mg/ml × 0.5 ml = 2.085 mg.

Conclusion: If you draw 0.5 ml, the actual dose is only 2.08 mg—well below the standard 2.5 mg.

2. Bangladesh Version (Example: Single-dose/specific specification)

Specification: 2.5 mg / 0.5 ml

Concentration: 5 mg/ml

If 0.5 ml is injected: Actual dosage received is 2.5 mg.

Conclusion: The design of the Bangladesh version aligns better with the standard clinical starting dose, ensuring the full required amount of medication is administered.

II. The Missing 0.4 ml: Why Can the Chinese Version Only Be Injected Four Times?

Regarding the Chinese version (10 mg / 2.4 ml), many users report: "There is 2.4 ml of liquid, and if I inject 0.5 ml each time, that should theoretically allow for 4.8 injections. Why can't I extract the remaining 0.4 ml after the fourth injection?"

This is caused by two factors:

1. Dead Space: Whether using an injection pen or a vial, there is physically inaccessible "dead space" at the bottom of the container and at the needle connection point.

2. Design Redundancy: When manufacturers design packaging with a total content of 10 mg, they usually base it on four standard doses (e.g., 2.5 mg each). Because the Chinese version has a lower concentration (4.17 mg/ml), delivering a 2.5 mg dose theoretically requires drawing 0.6 ml (2.5 mg ÷ 4.17 mg/ml ≈ 0.6 ml); drawing 0.6 ml four times uses up exactly 2.4 ml. However, if you only draw 0.5 ml, there is theoretically 0.4 ml left over, but this residual liquid often cannot be effectively utilized due to fluid clinging to the container walls and the limitations of dead space.